EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nitrosylcobalamin Selectively Targets Tumors via Cobalamin Uptake and Lysosomal Processing

Joseph A Bauer, Annette M Sysel

Frontiers in Bioscience-Elite · 10.03.2026 · 18 (1)

DOI: 10.31083/fbe42272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Elite, online erschienen am 10.03.2026. Verfasst von Joseph A Bauer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Nitric Oxide Services, LLC, Akron, OH 44312, USA. Hauptthemen laut MEDLINE: Vitamin B 12, Lysosomes, Nitroso Compounds, Neoplasms. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nitrosylcobalamin (NO-Cbl) is a vitamin B12 analog designed to exploit the “Trojan horse” vulnerability created by the heightened need of cancer cells for cobalamin and one-carbon metabolism. Building on our recent biophysical studies confirming the affinity of NO-Cbl for intrinsic factor, this work aimed to investigate the mechanistic basis for the selective anticancer activity of NO-Cbl through the cobalamin transport axis and lysosomal processing. Materials and Methods: Human cancer cell lines (NIH-OVCAR-3, MCF-7, WM9, and DU145) were cultured and transfected to overexpress transcobalamin II (TCII). Cell proliferation and cytotoxicity were measured using the sulforhodamine B (SRB) assay. TCII-R (CD320) expression was quantified by flow cytometry. The impact of anti-CD320 antiserum and lysosomal alkalization (chloroquine) on NO-Cbl activity was assessed.

Results

Antiserum inhibition of the TCII receptor resulted in dose-dependent inhibition of NIH-OVCAR-3 and MCF-7 cell proliferation. Lysosomal alkalinization by chloroquine pretreatment abrogated NO-Cbl-induced cytotoxicity in OVCAR-3 cells. Flow cytometric analysis demonstrated an inverse correlation between TCII-R (CD320) expression (MFI ratio) and NO-Cbl ID50. TCII overexpression significantly reduced NO-Cbl ID50 in NIH-OVCAR-3 cells.

Conclusion

NO-Cbl utilizes tumor cell cobalamin transport and processing pathways to deliver nitric oxide selectively to cancer cells. These results, integrated with recent binding studies, validate NO-Cbl as a cobalamin-based targeted anticancer agent with efficacy in tumors expressing high levels of TCII and CD320.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vitamin B 12LysosomesNitroso CompoundsNeoplasmsAntineoplastic AgentsHumansCell Line, TumorCell ProliferationTranscobalaminsReceptors, Cell SurfaceAntigens, CD

Stichwörter der Autor:innen

CD320TCIIcancercobalaminlysosomenitrosylcobalamintranscobalamin

Substanzen

Vitamin B 12nitrosylcobalaminNitroso CompoundsCD320 protein, humanTranscobalaminsAntineoplastic AgentsReceptors, Cell SurfaceAntigens, CD

Autor:innen und Institutionen

  • Nitric Oxide Services, LLC, Akron, OH 44312, USA.
  • Bauer Research Foundation, Inc., Akron, OH 44312, USA.

Zitieren

APA

Bauer, J. A., & Sysel, A. M. (2026). Nitrosylcobalamin Selectively Targets Tumors via Cobalamin Uptake and Lysosomal Processing. Frontiers in Bioscience-Elite, 18(1). https://doi.org/10.31083/fbe42272

Vancouver

Bauer JA, Sysel AM. Nitrosylcobalamin Selectively Targets Tumors via Cobalamin Uptake and Lysosomal Processing. Frontiers in Bioscience-Elite. 2026;18(1). doi:10.31083/fbe42272

BibTeX
@article{Bauer2026,
  author = {Bauer, Joseph A and Sysel, Annette M},
  title = {Nitrosylcobalamin Selectively Targets Tumors via Cobalamin Uptake and Lysosomal Processing},
  journal = {Frontiers in Bioscience-Elite},
  year = {2026},
  volume = {18},
  number = {1},
  doi = {10.31083/fbe42272}
}
Kostenlos starten →